Moreover, loss of heterozygosity for M6P/IGF-2R was found with point mutations in the other allele in 70% of patients with HCC, and some of these mutations resulted in disruption of ligand binding (Byrd et al, 1999; Devi et al, 1999). This evidence concerns the gene IGF2R and hepatocellular carcinoma.